– Linda Powers, Cofounder and Managing Director of Toucan Capital, is interviewed by GEN’s Editor in Chief, John Sterling

PodcastsResourcesTranslational MedicineCell therapyClinical trialDrug research and developmentEmbryonic stem cellsGenetic engineeringGenetic Engineering and BiotechnologyMedicineMedicine, Diagnosis, and TherapeuticsPharmacologyPluripotent stem cellsRegenerative engineeringResearch and developmentResearch resourcesStem cell engineeringStem cellsTherapeuticsTranslational medicine
Previous articleScientists Disprove Proposed Theory of Nervous System Development
Next articleThe Genome Center at Washington University Adds 21 Illumina Sequencers
Also of Interest
Related Media
How Blood That Leaks into the Brain Makes Immune Cells Toxic
Charms to Soothe the Savage Microbiome
ChatGPT-Like Model “Speaks Protein” to Speed Drug Discovery
Breath Can Deepen Our Understanding of the Microbiome
Base Editors and Prime Editors Begin to Realize Their Clinical Promise
Prospects for the Oral Delivery of Biopharmaceuticals
BIO CEO Rachel King Outlines Industry’s Challenges on “Close to the Edge”
Carl Icahn States His Case for Change at Illumina on “Close to the Edge”
Celebrating DNA: Matthew Cobb’s Reflections on the Double Helix
Emerging Markets Collaborate to Succeed in Post-Pandemic World
Book Review: The Exceptions
Search and Replace: Andrew Anzalone Details How Genome Editing Went Prime Time on “Close to the Edge”